News Hub | News Direct

New Device is Helping Patients Make Strides with their Mobility

YourUpdateTV

For those living with mobility impairments, wheelchairs, walkers and canes are a necessity for everyday life. While technological advancement has completely transformed almost every sector over the last century, innovation in mobility aids has largely remained the same. Recently, Founder and CEO of CIONIC, Jeremiah Robison, as well as Patty Glatfelter, a multiple sclerosis patient whose life has been transformed thanks to the Cionic Neural Sleeve, conducted a satellite media tour to share insights on the Cionic Neural Sleeve that's earned recognition as one of Time's Best Inventions of 2023. A video accompanying this announcement is available at: https://youtu.be/ZyJLaAuRp2c People living with mobility impairments are asking for, and deserve, better tools, harnessing the power of modern technology. Motivated by his daughter Sofia’s mobility challenges from cerebral palsy, tech innovator Jeremiah Robison founded CIONIC to harness the technological advances in continuous diagnostics and machine learning to help the mobility impaired not only regain mobility in the moment, but potentially improve it by strengthening and retraining the body over time. CIONIC is a neurotech company on a mission to superpower the human body to reach its fullest potential. CIONIC’s vision is a world beyond disability and limitations, enabled by personalized healthcare technology. The company’s premier product, the FDA-cleared Cionic Neural Sleeve, is changing the lives of people with upper motor neuron conditions (multiple sclerosis, stroke, cerebral palsy, spinal cord injury and more) drastically increasing their ability to walk, move and balance. Voted one of Time’s Best Inventions of 2023, The Cionic Neural Sleeve analyzes, predicts, and augments muscles in the leg to improve walking, updating with each step the wearer takes. To learn more visit cionic.com Jeremiah Robison Bio Jeremiah Robison is the Founder and CEO of CIONIC, an innovative company that builds lightweight and durable bionic clothing driven by powerful algorithms that adapt in real-time to each individual's mobility needs. He started the company in 2018 after his daughter was diagnosed with cerebral palsy and he was frustrated at the lack of effective technology available to help improve her mobility. Four years later, CIONIC introduced the breakthrough, FDA-cleared Cionic Neural Sleeve, the first product to combine sensing, analysis and augmentation into a wearable garment. Prior to CIONIC, Jeremiah spent twenty years at the intersection of data, algorithms, and the human body, driving innovation in sensing and machine learning at Apple, Openwave Systems, Slide, and Jawbone. Jeremiah has a BS and MS in Computer Science from Stanford University. About Patty Glatfelter Patty Glatfelter, 69, a Florissant, CO resident who has had multiple sclerosis (MS) for 37 years, has been using the Cionic Neural Sleeve for almost a year now. Patty, a former physical therapist, retired back in 2008 because of her limitations to provide care due to her MS. Before the Cionic Neural Sleeve, she couldn’t walk 50 feet and experienced periods of remissions, as well as stages where she relied on a walker, cane, and wheelchair. It was a rollercoaster ride for about eight to ten years. Her doctor even thought that within the first three to five years of her MS diagnosis, she would be in a wheelchair permanently. Her quality of life was limited. She had to cook sitting down and could stand for about 15 minutes before needing a break. She couldn’t take socks out of the dryer or go for walks outside of her house on the mountains alone. Ever since she started using the Cionic Neural Sleeve, she instantly saw a difference. She notes that she was “astounded by how well [I] was walking.” The Cionic Neural Sleeve has restored her ability to do many everyday things, including taking clothes out of the dryer, going for walks, taking vacations, climbing lighthouses and seeing friends and family. She even notes that she is better now than she was ten years ago. She describes the experience as “a perfect storm in a good way.” Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 19, 2024 12:29 PM Eastern Standard Time

Video

Start the Year Off Strong! Daily Wins, Lasting Changes: Achieve Your Health Goals with ‘Small Steps, Big Wins’

YourUpdateTV

As we step into the new year, many of us are looking for realistic ways to lose or maintain weight and achieve our health goals without the stress of a drastic transformation. Recently, registered dietitian-nutritionist, Scott Keatley, conducted a satellite media tour to share easy and sustainable tips to lose weight without completely overhauling your diet and routine. A video accompanying this announcement is available at: https://vimeo.com/903460368/bc03736ece?share=copy To help people with their New Year’s health resolutions, food tracking and nutrition app, MyFitnessPal, launched the free Small Steps, Big Wins plan. The one-week challenge introduces seven small changes that can have a big impact on health goals long-term across topics such as protein, sugar, hydration and more. If you are trying to lose weight in the new year, the Small Steps, Big Wins plan can help you accomplish your goal through small changes, tips, food swaps, and daily affirmations. This plan is right for you if you are: looking to lose weight but don’t want to completely overhaul your diet and routine, ready to make small daily changes that you can stick to long term or looking for easy tips and advice to keep you feeling motivated all year. Tracking food with MyFitnessPal not only holds you accountable, but it’s also incredibly empowering to learn more about how your body responds to nutrition. Tracking allows you to understand the quantity (calories) and quality (macros - protein, fat, and carbs) of what you eat. It can be difficult to make sure you are getting enough nutrients, such as protein and fiber, without tracking with a tool, like MyFitnessPal. If you want to start the year off strong, MyFitnessPal can provide inspiration on making small daily changes that add up to big improvements over time so that your resolutions last past January! Whether you're looking for healthy recipes, nutrition insights, food swaps, or workouts; the app is like having a nutritionist, personal trainer and coach right on your phone. If you’re interested in participating, simply download the free MyFitnessPal app on iOS and Android and join the Small Steps, Big Wins Plan today. You can join at any time and commit to making small changes to your daily routine for 7-days to kick-start the new year with a step in the right direction towards your wellness goals. To learn more visit myfitnesspal.com, or visit the Apple App store or Google Play store to download the app today. About Scott Keatley Scott Keatley is a Registered Dietitian-Nutritionist and member of MyFitnessPal’s Advisory Council. He is an active member of the Academy for Nutrition and Dietetics. Scott holds a master’s degree in dietetics from Iowa State University, a BS in Food and Nutrition from Brooklyn College and completed training at the Brooklyn Hospital and the H. Lee Moffitt Cancer Center & Research Institute, a nonprofit cancer treatment and research center. In addition to his clinical dietitian work, Scott’s wellness contributions include NBC News, U.S. News & World Report, Cosmopolitan, Prevention and Yahoo Health. Additionally, Scott received The Media Excellence Award from the New York State Academy of Nutrition and Dietetics in 2023. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 16, 2024 04:37 PM Eastern Standard Time

Video

Taking the Guesswork Out of Finding the Right Therapist with Two Chairs

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/_XF1w-pVxZs While more Americans are seeking therapy than ever before, many people are matched with the wrong therapist. Two Chairs, the leader in connecting patients to the right therapist, has developed a solution called Matchmaker, an industry-leading technology platform that expertly connects people with the right therapist based on their health history, personal background, and clinical needs. Research shows that a strong client-therapist relationship is the key to great therapy but finding the right therapist can feel overwhelming. Knowing where to start and what makes a great patient-therapist match saves time and increases the likelihood of success. Data shows that the majority of people attend just one therapy session before quitting: ● 1 in 5 patients quit therapy prematurely because they don’t trust their therapist. ● Data finds that a strong patient-therapist relationship is the single best predictor of therapy success. ● Recent research shows that an average 15-20 sessions are needed for 50% of patients to recover. When Two Chairs hires a new therapist, Matchmaker analyzes their strengths, experiences, and skill sets, zeroing in on clinical presentations, diagnoses, focus areas, and demographics. For example, a therapist highly skilled in treating panic disorders may be less adept at addressing postpartum depression. Conversely, a clinician who has limited experience in Acceptance and Commitment Therapy may demonstrate a high level of expertise in utilizing Dialectical Behavior Therapy. This meticulous process ensures that the precise therapist-patient pairing is fine-tuned to match an individual's needs. Two Chair’s Matchmaker process considers over 300 factors, including therapy types (such as dynamic, emotion-focused, cognitive-behavioral, etc.), clinical styles, specific disorder expertise (anxiety, mood, trauma, addiction, eating, personality, etc.), life stages, relationships, identity, and more. Additionally, therapists can stipulate therapeutic approaches they choose not to practice, serving as a safeguard for both patients and clinicians. This comprehensive analysis ensures a tailored and optimal match for individuals seeking therapy. Established with the goal of providing the highest quality outpatient mental health care system in the United States, Two Chairs boasts an impressive patient retention rate, with 90% of their patients continuing to a fourth session—significantly surpassing the national average of 33%. Key to their treatment success is one of the most rigorous and sophisticated clinician-patient matching processes on the market. Two Chairs’ newly launched Matchmaker features further empower clinicians to practice at the top of their license, allowing them to focus on cases they are most skilled in treating. On January 10th, a media tour was conducted featuring Colleen Marshall, Vice President of Clinical Care at Two Chairs and a Licensed Marriage and Family therapist, to discuss the new Matchmaker feature and the importance of measuring outcomes to ensure clients get better faster. With a growing team of 500 licensed clinicians across 90 areas of expertise, Two Chairs has more than 20 million covered lives. Topics that Colleen Marshall discussed during the media tour included: ● Why a strong client-therapist relationship is crucial for effective therapy. ● Why it’s important to prioritize your mental health and destigmatize getting help. ● Reasons why people quit therapy, emphasizing the importance of a good therapist match for a long-term relationship that will lead to better outcomes. ● Why Two Chairs' developed the Matchmaker feature, delving into how it works to improve therapist-patient connections. For more information, visit TwoChairs.com About Two Chairs Two Chairs was founded in 2017 with a mission to build a world where everyone has access to exceptional mental healthcare. We're creating a better experience for both patients and clinicians by starting with an in-depth, research-backed matching process to ensure the ideal patient-therapist fit, offering hybrid care that gives patients and clinicians flexibility between in-person and virtual sessions, and measuring outcomes to ensure patients get better faster. With a growing team of 50 licensed clinicians across 90 areas of expertise, Two Chairs has more than 20 million covered lives Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 16, 2024 10:00 AM Eastern Standard Time

Video

New Year, Healthiest You: Real Talk About Weight Loss Medication

YourUpdateTV

It’s that time of year again - New Year, Healthiest You! When we think about health goals which often include weight management, there is no avoiding the white hot topic of weight loss medications. Recently, Hims and Hers medical experts, Dr. Craig Primack, Leading Obesity Medicine Expert and SVP Weight Management and Dr. Jessica Yu, Clinical Psychologist and Sr. Director of Patient Experience, participated in a nationwide satellite media tour to discuss weight loss medication, how to achieve sustained success, and the connections between emotions, weight management and mental health. A video accompanying this announcement is available at: https://youtu.be/3EJ0WhNYiEE With stats showing 7 in 10 American adults are overweight or obese, it’s no surprise the conversation around weight loss medication took off like wildfire and it’s not stopping anytime soon. Leading health & wellness platform, Hims & Hers, recently launched Weight Loss by Hims & Hers, a comprehensive and customizable prescription based alternative to the GLP-1’s (i.e. Ozempic, Wegovy, Mounjaro) that have dominated headlines recently. Addressing the major roadblock of cost, accessibility and lasting results - this personalized weight management program is affordable (no insurance needed), offers oral based medication, and provides customers with ongoing content and coaching throughout their health and fitness journey. Weight loss is both a physical and psychological endeavor. By addressing underlying factors that contribute to weight gain including nutrition, behavior, and movement - Hims & Hers creates a tailored holistic plan in order for customers to lose and keep off the weight leading to long-term health benefits. For more information, visit hims.com or forhers.com About Dr. Craig Primack Dr. Craig Primack MD, FACP, FAAP, FOMA is a physician specializing in obesity medicine. He is the co-founder of Scottsdale Weight Loss Center in Scottsdale, Arizona, where he began practicing full-time obesity medicine. Primack completed a combined residency in Internal Medicine and in Pediatrics at Banner University- Phoenix, and Phoenix Children's Hospital. Dr. Primack received post-residency training in Obesity Medicine and is one of about 7,000 physicians in the US certified by the American Board of Obesity Medicine. He completed his undergraduate studies at the University of Illinois and subsequently attended medical school at Loyola University - The Stritch School of Medicine. Dr Primack routinely does media interviews regarding weight loss and regularly speaks around the country educating medical professionals about weight loss and obesity care. He is co-author of the book, “Chasing Diets”. About Dr. Jessica Yu Dr. Jessica Yu is the Senior Director of Patient Experience at Hims & Hers. She is a clinical psychologist whose professional mandate has been to bring evidence-based mental healthcare to those in need in new and interesting ways. At Hims & Hers, she works to uphold psychological principles at every step of the mental health journey, develop new ways of helping people achieve their emotional and mental health goals and contribute to thought leadership. Dr. Yu holds a Bachelor of Arts degree in Human Biology from Stanford University and a Ph.D. in Clinical Psychology from Rutgers, the State University of New Jersey. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 12, 2024 02:18 PM Eastern Standard Time

Video

Defense Acquisition University (DAU) to Support NCMA Nexus 2024

National Contract Management Association

The National Contract Management Association (NCMA) is pleased to announce the collaboration with the Defense Acquisition University (DAU) for the inaugural Nexus 2024 conference, scheduled from March 3-6 in Jacksonville, FL. This strategic partnership is a significant milestone for NCMA as it reinforces the commitment to advancing the knowledge and skills of the defense acquisition workforce. Notably, participants in Nexus 2024 will benefit from transferable credits toward their certifications, making this collaboration with DAU particularly valuable for professionals seeking career development opportunities. Nexus 2024, offers a unique platform for cross-functional collaboration for both government and industry to address pressing issues in federal procurement, including supply chain risk, cybersecurity, and sustainability. The event encourages joint efforts in innovation, strategic discussions, case studies, hackathons, and real-world problem-solving, providing deployable solutions for attendees. The co-hosted event aligns seamlessly with the new Better Contracting Initiative (BCI), emphasizing that multi-functional groups come together to learn the acquisition lifecycle side by side, promoting a comprehensive understanding of each’s others perspective job functions along with federal procurement challenges. One of the emcees for Nexus 2024 is DAU’s Professor of Program Management, Julie Knechtel, expressed her excitement about the event, stating, "I am excited to be part of an event that brings together diverse perspectives and expertise in defense acquisition. It is a great opportunity to train as we work, leverage the expertise of multi-functional teams, and enhance the skills needed to tackle the evolving challenges in federal procurement collaboratively." NCMA's Chief Executive Officer, Kraig Conrad, commented on the natural fit between NCMA and DAU, saying, "The collaboration with DAU at Nexus 2024 exemplifies our shared commitment to advancing the knowledge and skills of the acquisition workforce. We are grateful for their support as together we drive better practices and better outcomes in acquisition and procurement.” Michelle Currier, NCMA's Chief Learning Officer, also shared her enthusiasm, stating, "The Nexus 2024 event underscores the importance of collaboration and continuous learning in federal procurement. DAU's support enhances the educational value of the event, aligning with the goals of not only NCMA, but the federal government overall." Nexus 2024 is open to all professionals involved in federal procurement, providing an ideal opportunity for integrated teams to learn and train together. For more information about Nexus 2024 and to register for the event, visit the NCMA website at http://www.ncmahq.org/nexus. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. DAU is the acquisition learning, development and talent management organization for the Department of Defense with a mission to provide a global learning environment to develop qualified acquisition, requirements, and contingency professionals who deliver and sustain effective and affordable warfighting capabilities. Nearly 160,000 acquisition professionals across all military services and Department of Defense agencies have access to career-long learning and support from DAU faculty and staff. Contact Details Holly DeHesa +1 281-865-3296 dominick.belfiore@ncmahq.org Company Website https://www.ncmahq.org

January 11, 2024 05:05 AM Eastern Standard Time

G Medical Innovations Announces First Half 2023 Financial Results and Provides Business Update

G Medical Innovations Holdings Ltd

G Medical Innovations Holdings Ltd. (Nasdaq: GMVDF) (“G Medical” or the “Company”), an early commercial stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2023. First Half 2023 Financial Results The Company reported total revenues for the six-month period ended June 30, 2023 in the amount of approximately $3.1 million, compared with approximately $1.9 million for the six months ended June 30, 2022 Cash and cash equivalents as of June 30, 2023, were $2,009 thousand, compared to $295 thousand as of December 31, 2022. The increase compared to December 31, 2022, mainly reflects less cash used in operating activities and lower investments in fixed assets during the six months ended June 30, 2022. Research and development expenses for the six months ended June 30, 2023, were $972 thousand, representing a decrease of $217 thousand compared to $1,189 thousand in the six months ended June 30, 2022. The decrease is related to the products segment and is mainly related to the decrease of salaries and related expenses as well as in subcontractors. Selling, general, and administrative expenses for the six months ended June 30, 2023, were $8,202 thousand, representing a decrease of $3,889 thousand compared to $12,091 thousand in the six months ended June 30, 2022. The decrease is related mainly to a decrease in share-based compensation expenses in the amount of $1,327 thousand and to a decrease in share issuance costs of 1,545 thousand. Net loss for the six months ended June 30, 2023, was $6,083 thousand, or $1.13 per share attributed to shareholders of the Company, compared to $ 13,287 thousand or after giving effect to the reverse stock split in 2022, $ 25.31 per share attributed to shareholders of the Company, in the six months ended June 30, 2022. The decrease in net loss was mainly attributed to the Company's COVID-19 business activities. Net cash used in operating activities during the six months ended June 30, 2023, was $7,254 thousand, compared to $16,424 thousand during the six months ended June 30, 2022. The decrease consists primarily of net loss and revaluation of liability in respect of derivative liabilities. “The Company expects growth in its patient monitoring business”, said Dr. Yacov Geva, Chief Executive Officer of G Medical. The complete report is available on the company’s website, https://gmedinnovations.com/investors About G Medical Innovations Holdings Ltd. G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch; and 31 different at-home health tests kits. In addition, the Company is developing its Wireless Vital Signs Monitoring System, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its future financial performance. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to maintain access to sources of liquidity; the Company’s ability to successfully market its products and services; the Company’s expectation regarding government and third-party payors providing adequate coverage and reimbursement for the use of its products and services, including the Company’s COVID-19 and other related testing services; the acceptance of its products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other medical device and at-home test kit businesses; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2023, and in any subsequent filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Investor Relations Contact G Medical Innovations Holdings Ltd. +972 8-958-4777 service@gmedinnovations.com Dr. Yacov Geva G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch; and 31 different at-home health tests kits. In addition, the Company is developing its Wireless Vital Signs Monitoring System, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility monitoring services and private monitoring services. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its future financial performance. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to maintain access to sources of liquidity; the Company’s ability to successfully market its products and services; the Company’s expectation regarding government and third-party payors providing adequate coverage and reimbursement for the use of its products and services, including the Company’s COVID-19 and other related testing services; the acceptance of its products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other medical device and at-home test kit businesses; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2023, and in any subsequent filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details Rina Bar +972 54-724-0412 rinab@gmedinnovations.com Company Website https://gmedinnovations.com

January 10, 2024 03:01 PM Eastern Standard Time

Human-augmented AI data marketplace Ta-Da debuts on strategic MultiversX incubator xLaunchpad

STORM Partners

Ta-Da, the platform revolutionizing AI data annotation, announces its highly anticipated debut on xLaunchpad, MultiversX’s strategic incubator. This collaboration sets the stage for a groundbreaking advancement in the secure and ethical development of AI, harnessing the power of human-validated data. Founded on over seven years of expertise in AI, Ta-Da leverages the power of MultiversX blockchain technology to disrupt conventional data collection methods. With its focus on video, audio, and image verticals, Ta-Da introduces a hybrid model of data annotation that blends quality, cost-effectiveness, and scalability. Addressing major challenges in AI development, such as bias and high data-related costs, this approach has already proven its efficacy with over 2.5 million tasks completed during its public beta phase. “The future of AI is not just about algorithms but about the quality and diversity of data that trains these algorithms,” says William Simonin, CEO of Ta-Da. “ Our launch on xLaunchpad is a pivotal step in realizing our vision of creating more effective AI systems by harnessing the power of human insight and the robustness of blockchain technology. ” xLaunchpad is the strategic incubator and acceleration platform of the MultiversX blockchain ecosystem. It is renowned for backing the most ambitious and impactful technologies in the web3 space, enabling them to leverage MultiversX’s highly scalable and secure blockchain network, which processes over 30,000 transactions per second at negligible cost. “ Ta-Da’s innovative model for AI data annotation aligns perfectly with our mission to foster technological advancements that have a profound global impact, ” said Beniamin Mincu, CEO and founder of MultiversX. “ Their debut on xLaunchpad is a testament to our commitment to nurturing projects that tap into the massive opportunities that emerge from the convergence of blockchain and AI. ” The collaboration between Ta-Da and xLaunchpad signifies a transformative movement in AI and blockchain technology. It not only propels Ta-Da’s mission forward but also reinforces MultiversX’s position as a leader in supporting revolutionary tech initiatives. This partnership is set to redefine the landscape of AI development, making it more accessible, diverse, and efficient. The public launch event of Ta-Da on xLaunchpad is taking place on February 09, 2024. For more information and to be part of this transformative journey, visit https://xlaunchpad.com/tada About MultiversX MultiversX is a highly scalable, secure, and decentralized blockchain network built from first principles, to solve the two fundamental problems critical for widespread, global adoption: a transition from dialup to broadband, and a significant UX paradigm shift. Distributed by STORM Partners. Contact Adrian Bono for interviews and quotes -adrian.bono@storm.partners or telegram @STORMPartners Contact Details Dan Voicu +1 561-325-8757 dan.voicu@multiversx.com

January 10, 2024 09:12 AM Eastern Standard Time

Image

5Scape VR Announces its Presale Going Live Today!

Spark Metro PR

In the thrilling realm of virtual reality (VR), 5th Scape stands as the gateway to the next big thing. Utilizing cutting-edge technology, 5th Scape promises a significant transformation in the online VR games platform niche, redefining the essence of immersive 3D gaming experiences. 5SCAPE Crypto Coins represent the first coins in the cryptocurrency world to offer exclusive access to premium VR content and devices, enhancing gaming experiences. Serving as a gateway to unlock special in-game features, these coins foster a dynamic community and present substantial growth potential within the virtual reality ecosystem. If you're interested in futuristic investment opportunities, cryptocurrency competes strongly with traditional avenues, and 5 Scape offers a rewarding future-proof investment. Click here to visit the 5 Scape Presale site Presale Countdown: 8 Hours Until Launch Prepare for an extraordinary journey into the limitless possibilities of virtual worlds! The 5th Scape team is thrilled to announce the presale launch happening TODAY in just 8 hours. This presale event introduces the 5SCAPE Coin, a token unlocking exclusive access to premium VR content, elevating gaming experiences to unparalleled heights. Get ready for an extraordinary journey into the limitless possibilities of virtual worlds! The 5th Scape team is thrilled to announce the upcoming presale launch, set to kick off in just 8 hours. This presale event introduces the 5SCAPE Coin, a token that will unlock exclusive access to premium VR content, elevating your gaming experiences to unparalleled heights. Presale Launch Details: Date: 09th January 2024 Time: 11 PM UTC +4 Total Funding Goal: $15 Million Click here to visit the 5 Scape Presale site 5SCAPE Coin - Your Key to Unmatched Virtual Reality Adventures At the center of the 5th Scape ecosystem, 5SCAPE coins are not just a currency but your ticket to a world where imagination meets innovation. As the presale events commence, game enthusiasts have the opportunity to be among the first to acquire 5SCAPE tokens, offering entry to exciting 3D VR games, powerful VR headsets with HDR quality, and ergonomically designed gaming chairs for utmost comfort during missions. Presale Highlights: The current price of 5Scape token at launch is $0.00187 Throughout all presale rounds, the 5scape token price is expected to appreciate by 400%, reaching a total value of $0.01. As the first VR ecosystem in the Ethereum crypto world, the 5th Scape project anticipates a reliable future without significant market competition. Early birds/Early enrollees will gain an exclusive advantage to access VR games and devices. Enjoy substantial discounts on all digital products with 5Scape tokens. Rest assured about data safety and confidentiality, protected by decentralized blockchain technology. Join Us in Redefining Reality 5th Scape is not just a project; it's a mission to reshape the virtual reality landscape. With a vision to be the forefront innovator in the VR industry, 5th Scape invites visionary investors, long-term investors, game developers, and gaming enthusiasts to join this thrilling and adventurous journey. Be part of the future of virtual reality gaming with 5scape. Don't Miss this fantastic opportunity to invest in 5th Scape, where technology and imagination converge to create a virtual world like never before. About 5th Scape: 5th Scape is a cutting-edge online VR games platform poised to redefine immersive gaming experiences. With the 5SCAPE Coin, 5th Scape offers exclusive access to premium VR content, animations, educational content, movies, and much more, creating a dynamic community within the virtual reality landscape. Follow 5thScape on social media for the latest updates: Twitter: @5th_scape Telegram: @fifthScape Discord: @5thscape Join the conversation using #5thScapeVR Contact Details Spark Metro Sumit Kumar +1 302-597-6768 sales@sparkmetro.com

January 09, 2024 04:53 AM Eastern Standard Time

Image

Newsletter - How G Medical Innovations is transforming telehealth and mobile cardiac telemetry in 2024

G Medical Innovations Holdings Ltd

A revolutionary chronic care management system that empowers patients to take control of their health A suite of sensors, such as 1-lead ECG, SPO2, temperature, BP, and weight scale, that can be used by the patients at home and transmit their vital signs and other measurements to the cloud in real-time. Portals and Smartphone Apps for the patients and physicians, where they can view trends and history, perform video conferences, write prescriptions and meeting summaries, and receive alerts for any abnormality or symptom detected. A secured HIPAA compliance cloud-based platform where the data from the sensors are stored, analyzed, and shared securely. We are thrilled to introduce our new flagship product, the Prizma, an ecosystem that empowers patients to take control of their health and enables physicians to monitor their patients and improve outcomes. Prizma consists of the following components: Prizma has many benefits for both patients and providers. For patients, it can improve their quality of life, reduce hospital visits, and lower their healthcare costs. For providers, it can enhance their efficiency, accuracy, and productivity. It can also empower patients to take control of their medical conditions. Prizma ecosystem allows physicians to offer their patients RPM and RPT services, which are covered by CPT codes and, on the one hand, improve patients' treatment and, on the other hand, allow the clinic to generate additional revenue streamline. We are proud of our innovation and believe that Prizma is a game changer in the healthcare industry and in the lives of our patients. Our expanded telehealth network and partnerships We are also excited to share with you that we have expanded our telehealth network and partnerships with leading healthcare providers and insurers across the country. We now offer our telehealth solutions and mobile cardiac telemetry services to more than 100 million members and patients, covering a wide range of cardiac conditions and needs. Our telehealth solutions and mobile cardiac telemetry services are designed to provide convenient, accessible, and affordable care to our customers and patients. Our telehealth solutions and mobile cardiac telemetry services are proven to improve outcomes, reduce costs, and enhance quality of life. Facts you may not be aware of The Triple Analysis you need to know about, how our service enhances your patient care in extra 2 unique steps. Did you know that at the end of each MCT study, the entire report undergoes a double screening to detect events that the device's algorithm did not detect in real-time? At G Medical, this is our unique approach: An AI-based algorithm conducts the first screen and is then verified by certified cardiac technicians. On average, 16% more events are identified during the end-of-study screening. We are committed to you and your patients, and we triple-check each case. The outcome justifies our efforts. Leading the 4 th healthcare revolution with our investment in R&D, quality assurance, and regulations We are committed to investing in research and development to bring you the most cutting-edge solutions for home hospitalization and remote treatment. These are the core values of the 4th healthcare revolution, which we are proud to be part of. Our R&D team is constantly working on enhancing our flagship product, the Prizma eco-system, as well as developing new sensors and monitoring solutions that are not available today. Prizma is a smart portable device that can monitor vital signs, detect abnormalities, and alert medical professionals in real-time. It can also sync with our cloud-based platform, where we can store, analyze, and share the data securely. We are excited to share our R&D efforts with you, and we look forward to launching these new features soon. As our customer, you will be the first to use them and enjoy the benefits of being part of the 4th healthcare revolution. Our culture and team spirit Finally, we want to acknowledge and celebrate our culture and team spirit that makes us who we are. We have fostered a collaborative, diverse, and inclusive work environment that values and respects each and every one of our team members. We have welcomed new talent and expertise to our team and provided opportunities for learning and development for our existing staff. Our team receives ongoing training and education from leading industry instructors, which keeps them up-to-date and enables them to provide you with our well-known high-service standards. In addition, our company culture reflects our commitment to delivering our well-known personal, attentive, and flexible service to our customers. We respect your preferences, adapt to your requirements, and ensure your satisfaction throughout the process. To conclude, We know that you have alternatives, and we are truly grateful and honored to have you as our valued customer and partner in this journey. We look forward to serving you and meeting your needs in the coming year and beyond. If you want to learn more about our telehealth solutions and mobile cardiac telemetry services, please visit our website at https://gmedinnovations.com/ or contact our sales team at support.us@gmedinnovations.com. You can also follow us on LinkedIn: https://www.linkedin.com/company/g-medical-innovations/ for more updates and news. Sincerely, Dr. Yacov Geva CEO and President of G Medical Innovations G Medical Innovations Holdings Ltd. is a health care company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both health care providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing multi-channel patient-worn biosensors with algorithms, to generate real time analysis and transmission that captures electrocardiography data continuously, including QT syndrome prolongation detection. In addition, the Company is developing its wireless vital signs monitoring system, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of independent diagnostic testing facility monitoring services and private monitoring services. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical Innovations is using forward-looking statements when it discusses: revenue growth and profitability in future periods; the launch of the Company’s CLIA lab in Austin, TX, the Company’s online store for its Prizma Monitoring Devices on Amazon Marketplace and the Company’s HTKs business and online stores; potential announcements with large homecare service companies and large distributors for devices and At Home Test Kits; and the Company’s plans to expand its line of monitoring products and services offered to patients, hospitals and clinics. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical Innovations could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,, including those discussed under the heading “Risk Factors” in G Medical’s Innovations Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on May 16, 2023, and our other filings with the SEC, which are available on the SEC’s website, www.sec.gov. Except as otherwise required by law, G Medical Innovations undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details Rina Bar +972 54-724-0412 rinab@gmedinnovations.com Company Website https://gmedinnovations.com

January 05, 2024 03:17 AM Eastern Standard Time

Image

Healthcare

New Device is Helping Patients Make Strides with their Mobility

Start the Year Off Strong! Daily Wins, Lasting Changes: Achieve Your Health Goals with ‘Small Steps, Big Wins’

Taking the Guesswork Out of Finding the Right Therapist with Two Chairs

New Year, Healthiest You: Real Talk About Weight Loss Medication

Defense Acquisition University (DAU) to Support NCMA Nexus 2024

G Medical Innovations Announces First Half 2023 Financial Results and Provides Business Update

Human-augmented AI data marketplace Ta-Da debuts on strategic MultiversX incubator xLaunchpad

5Scape VR Announces its Presale Going Live Today!

Newsletter - How G Medical Innovations is transforming telehealth and mobile cardiac telemetry in 2024